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The retroviral oncoprotein v-Rel is a transcriptional activator in the Rel/NF-KB family of eukaryotic transcription 
factors. v-Rel malignantly transforms a variety of cell types in vitro and in vivo, and its transforming activity is 
dependent on the ability of v-Rel to bind to DNA and activate transcription. In this report, we used the yeast 
two-hybrid assay to identify proteins that interact with C-terminal sequences of v-Rel that are needed for tran­
scriptional activation and transformation. One protein, Trip6, that we identified in this screen was previously 
identified as a thyroid hormone receptor-interacting protein. Trip6 is a member of a subfamily of LIM domain- 
containing proteins that are thought to transport intracellular signals from the cell surface to the nucleus. By 
several criteria, we show that sequences from Trip6, which include the LIM domains, behave as a coactivator 
for transcriptional activation by v-Rel. That is, a GAL4-Trip6 fusion protein can activate transcription in yeast 
and chicken cells, Trip6 can enable C-terminal sequences of v-Rel to activate transcription in yeast, and Trip6 
can enhance activation by v-Rel from a k B site reporter plasmid in yeast. Although full-length Trip6 localizes 
to adhesion plaques, deletion of N-terminal sequences allows human Trip6 to enter the nucleus of chicken cells. 
Lastly, Northern blotting shows that Trip6 mRNA is expressed in many human tissues. Coexpression of Trip6 
does not affect the transforming activity of v-Rel. Taken together, our results indicate that Trip6 may be a 
protein that is important for the ability of v-Rel to activate transcription and transform cells, and may represent 
a potential target for blocking Rel-mediated oncogenesis and transcriptional activation.
v-Rel Retroviral oncogene Trip6 Coactivator LIM domain Transcription factor 
Malignant transformation NF-kB Two-hybrid assay
THE v-Rel oncoprotein, encoded by the highly onco­
genic avian Rev-T retrovirus, can transform a variety 
of hematopoietic cells in vitro and in vivo [reviewed 
in (14)]. v-Rel is a member of the Rel/NF-KB family 
of eukaryotic transcription factors. Like other mem-* 
bers of this family, v-Rel has an N-terminal domain 
of approximately 300 amino acids, the Rel Homology 
(RH) domain, that contains sequences important for 
DNA binding, the formation of homo- and hetero­
dimers, and nuclear localization. Residues located C-
terminal to the RH domain in v-Rel are important for 
transcriptional activation in vertebrate cells (28,29, 
34).
Several lines of evidence suggest that v-Rel 
must form homodimers, bind to DNA, and activate 
transcription to effect malignant transformation of 
chicken spleen cells. First, a v-Rel mutant that cannot 
form homodimers, but can still form heterodimers 
with cellular Rel family proteins, cannot transform 
cells (32). Second, v-Rel mutants that are temperature
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sensitive for transformation are also temperature sen­
sitive for DNA binding (31). Third, deletions that 
remove the C-terminal sequences involved in tran­
scriptional activation by v-Rel also render it transfor­
mation defective (28,29). However, the C-terminal 
sequences of v-Rel cannot be replaced by a heterolo­
gous transcriptional activation domain (16) and not 
all v-Rel mutants that can activate transcription can 
likewise transform cells (5). Thus, the C-terminal 
sequences of v-Rel represent a transformation-spe­
cific domain that is likely to participate in transfor­
mation by activating transcription of specific genes’ 
and the ability of v-Rel to activate transformation- 
specific transcription may require a distinct molecular 
pathway.
The C-terminal sequences of v-Rel contain multi­
ple transcriptional activation domains that can act in 
a cell type-specific manner (13,19,21,28,34). For ex­
ample, although GAL4 or LexA fusion proteins con­
taining C-terminal sequences of v-Rel can activate 
transcription in chicken cells (26,28,29), such pro­
teins cannot activate transcription in yeast (21). 
Therefore, C-terminal sequences of v-Rel may re­
quire cell type-specific coactivators to activate tran­
scription. Moreover, the ability of sequences in v-Rel 
to  interact directly with general transcription factors, 
such as TFIID and TFIIB, is controversial (22,34).
In this report, we demonstrate that Trip6. a LIM 
domain-containing protein originally identified as an 
interacting partner with the thyroid hormone receptor 
(23), can also interact with C-terminal sequences of 
v-Rel in a yeast two-hybrid screen. Moreover. Trip6 
fulfills certain requirements of a transcriptional adap­
tor or coactivator for v-Rel.
MATERIALS AND METHODS 
Yeast Two-Hybrid Screening
Yeast two-hybrid screening using C-terminal se­
quences of v-Rel fused to the GAL4 DNA binding 
domain (pGB-3'v-Rel) was performed in Y190 cells, 
which contain GAL4 site H1S3 and lacZ reporter loci 
as described (11). The human B-cell two-hybrid 
cDNA library was kindly provided by Steven Elledge 
(11). Yeast transformants (8 x 105) were plated and 
selected for histidine auxotrophy in the presence of 
25 mM 3-amino-triazole (3-AT). Colonies that grew 
on the initial plates were picked and streaked on 
plates containing 35 mM 3-AT and were then sub­
jected to a second screen for lacZ expression by per­
forming a P-galactosidase overlay assay (2). Positive 
cell clones were grown in the presence of tryptophan 
for several passages, and were screened for loss of 
the T’/fP/-containing pGB-3'v-Rel plasmid. Cells
containing only the cDNA library plasmids were 
mated to cells containing pGB-3'vRel, pGBT9 
(GAL4 DNA binding domain alone), or expression 
plasmids for GAL4 fused to p53, lamin, SNF1, or 
CDK. (i-Galactosidase overlay assays were performed 
on the diploid yeast cells to confirm the specificity 
of the interactions.
Plasmids
Plasmid GBT9, containing codons 1-147 of 
GAL4, was used for the expression of GAL4 fusion 
proteins in yeast. To create pGB-3'v-Rel, a Hincll 
fragment containing 3'v-Rel sequences encoding aa 
332-503 was subcloned into plasmid GBT9 that had 
been digested with BamHl and treated with Klenow. 
To create pGB-Trip6, a Bglll fragment containing 
Trip6 sequences encoding aa 116-476 was excised 
from the cDNA two-hybrid library plasmid and was 
subcloned into the BamHl site of pGBT9. To create 
pGB-3'c-Rel, an EcoRI fragment from pSG-3'mC 
(28) containing 3' sequences from mouse c-Rel was 
subcloned into the EcoRI site of pGBT9.
To create pSG5-FLAG-ANTrip6, Trip6 sequences 
were recovered from the two-hybrid cDNA library 
plasmid by digestion with EcoRI. treatment with 
Klenow, and subsequent digestion with Bglll. The 
Trip6 fragment was then subcloned into pSG5-FLAG
(18) that had been digested with EcoRV and BamHl. 
The expression plasmid for FLAG-tagged full-length 
Trip6 9 (aa 2-476) was created by PCR using an 
upstream adaptor primer (5'-GACGAATTCCGGGC 
CCACCTGGCTTC-3') corresponding to the 5' end 
of human trip6 and containing a flanking EcoRI site 
and a downstream T3 primer. The PCR product was 
digested with EcoRI and subcloned into the EcoRI 
site of pcDNA3-FLAG (30).
To create pJK-Trip6 for the expression of FLAG- 
ANTrip6 in yeast, an EcoRI to Bglll fragment from 
pSG5-FLAG-Trip6 was first subcloned into pGEM-4 
that had been digested with EcoRI and BamHl to cre­
ate pGEM4-FLAG-Trip6. This plasmid was then di­
gested with EcoRI, treated with Klenow, and digested 
with Sail. The fragment containing FLAG-Trip6 was 
subcloned into vector pJKTPI (a kind gift of Joanne 
Kamens) that had been digested with Smal and Sail. 
Yeast plasmids BC102, BC-v-Rel, and reporter plas­
mid IgK6 have been described previously (20).
Plasmid SG424, encoding aa 1-147 of GAL4, was 
used to express GAL4 fusion proteins in chicken cells 
(27). GAL4 producer plasmids SG424, SG-3'c-Rel 
(mouse c-Rel), and SG-3'v-Rel and GAL4 site re­
porter plasmid G5BCAT have been described pre­
viously (28). pSG-Trip6 for the expression of GAL4- 
Trip6 was made by subcloning a Hindlll to Sail frag­
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ment containing the GAL4-Trip6 fusion from pGB- 
Trip6 into pSG424 digested with Hin&Ul and Sail.
Plasmid MH105 is a spleen necrosis virus vector 
for the expression of \-rel and neo (32). To create 
pMH-v-Rel/FLAG-Trip6, an Ncol to blunt-ended 
BglM fragment from pSG5-FLAG-Trip6 was sub­
cloned into pMH105 that had been digested with 
Rsrl, treated with Klenow, and then digested with 
Ncol, thus replacing the 3' neo gene with FLAG- 
Trip6. To create pMH-FLAG-Trip6, pMH-v-Rel/ 
FLAG-Trip6 was digested with Xbal and religated to 
remove the \-rel sequences.
Reporter Gene Assays in Yeast and 
Tissue Culture Cells
lacZ reporter gene assays were performed in yeast 
by using either Y190 cells with an integrated lacZ 
reporter gene driven by GAL4 DNA binding sites 
(11) or EGY40 cells transformed with IgK6, which 
is a lacZ reporter plasmid containing six upstream kB 
DNA binding sites (20). The yeast cells were trans­
formed with the indicated producer plasmids and 
lacZ expression in liquid cultures was determined as 
described previously (20).
CAT reporter gene assays were performed in CEF 
using 5 (ig of pSG424-based GAL4 expression plas­
mids and 5 ^g of GAL4 site reporter plasmid G5B- 
CAT as described (30). For normalization, cells were 
cotransfected with 1 jig of pCMV-P-gal. Forty-eight 
hours posttransfection, cells were harvested and liq­
uid (i-galactosidase assays were performed to deter­
mine transfection efficiency. CAT assays were then 
performed on extracts containing equal p-galactosi- 
dase activity. Thin-layer plates were analyzed and 
quantitated using a Bio-Rad Molecular Imager.
Indirect Immunofluorescence and Western Blotting
Indirect immunofluorescence with anti-Rel antise­
rum was performed as described previously (31). In­
direct immunofluorescence and Western blotting with 
the M2 anti-FLAG antibody (Sigma) were performed 
as described (30). For indirect immunofluorescence, " 
cells were washed with PBS, fixed for 10 min in 4% 
paraformaldehyde, treated for 2 min with 0.2% Triton 
X-100, and blocked for 30 min with 20% goat serum 
in PBS before incubating with 1-2.5 (ig/ml M2 anti­
body for 1 h in the presence of 20% goat serum. After 
washing, cells were incubated with FITC-conjugated 
goat anti-mouse antiserum for 1 h at a dilution of 
approximately 1:80. Cells were then washed with 
PBS, mounted on microscope slides, and imaged with 
an Olympus inverted confocal microscope. Western 
blotting on lysates of transformed spleen cells was
performed with anti-v-Rel as described previously 
(31).
Chicken Spleen Cell Transformation Assays
Chicken spleen cell transformation assays were 
performed as described previously (31) by electropor­
ating fresh spleen cells from 19-day-old chickens 
(Spafas, Inc.) with 10 (ig of SW253 Rev-A helper 
virus plasmid and 20 (ig of pMH105 or pMHv-rel/ 
FLAG-AN-Trip6. Cells were then plated for 4 days 
in DMEM containing 20% fetal calf serum, after 
which cells were suspended in soft agar, and colonies 
were scored 10-14 days later. Colony numbers were 
normalized to the number of colonies obtained with 
pMH105.
Northern Blotting
Multiple human tissue RNA filters were purchased 
from Clontech. A probe for Trip6 was prepared by 
random primer HP-labeling of an Xhol fragment en­
compassing the Trip6 sequences from the cDNA li­
brary plasmid isolated in the yeast two-hybrid screen.
RESULTS
Trip6 Interacts With C-Terminal Sequences o f  v-Rel 
in a Yeast Two-hybrid Assay
We previously showed that C-terminal sequences 
of v-Rel, which can activate transcription in chicken 
cells, cannot activate transcription in yeast (21,26, 
28). Therefore, we used a GAL4 fusion protein 
(GAL4-3'v-Rel) containing the C-terminal sequences 
of v-Rel as bait in a yeast two-hybrid screen to iden­
tify interacting proteins. Because v-Rel primarily 
transforms lymphoid cells, a human B-cell cDNA li­
brary was screened. After screening 8 x 105 yeast 
transformants, we identified three positive clones. 
Restriction enzyme digestions and preliminary DNA 
sequencing indicated that two of these cDNAs were 
identical to one another and contained approximately 
1.4 kbp of sequences encoding a portion of Trip6, a 
protein initially identified in a two-hybrid screen as 
interacting with the thyroid hormone receptor (23).
The GAL4 activation domain-Trip6 fusion protein 
(GAD-Trip6) that interacted with GAL4-3'v-Rel en­
coded aa 116-476 of the full-length human Trip6 
protein (35) (Fig. 1 A) and included the three C-termi­
nal LIM domains. The interaction of v-Rel sequences 
with Trip6 is specific: in two-hybrid assays Trip6 in­
teracted with GAL4-3'v-Rel, but not with the GAL4 
DNA binding domain alone or unrelated GAL4 fu­
sion proteins, including GAL4-p53, GAL4-lamin, 
GAL4-SNF1, and GAL4-CDK2 (data not shown).
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FIG. I. Trip6 can enable GAL4-3'v-Rel to activate transcription in yeast. (A) Schematic of full-length Trip6 (which contains an N-terminal 
proline-rich domain and three C-terminal LIM domains) and the N-terminally deleted portion of Trip6 encoded by the cDNA that was 
isolated in the two-hybrid screen. (B) Yeast strain YI87 cells, containing an integrated GAL4 lacZ reporter locus, were transformed with 
plasmids encoding the indicated GAL4 proteins. Liquid (3-galactosidase assays were performed in triplicate, and the values were then 
averaged and normalized to the value obtained for G A L4(l-l47). Shown at the top of (B) are the generalized structures of v-Rel and c- 
Rel. In these figures, the white box with Rel indicates the approximate extent of the Rel Homology DNA binding/dimerization domain, 
while the gray shaded areas indicate the C-terminal transactivation domains. Numbers above the figures indicate the aa sequences included 
in all proteins. (C) Yeast strain Y190 cells, containing integrated lacZ and HIS3 GAL4 site reporter loci, were cotransformed with plasmids 
for the expression of the indicated GAL4 proteins and with a plasmid for the expression of FLAG-ANTrip6 (+) or the corresponding empty 
expression vector (-). Cells were grown in the presence of 15 mM 3-amino-triazole to ensure continued expression of the HIS3 gene. Liquid 
ft-galactosidase assays were performed in duplicate and values are expressed as average units of (3-galactosidasc activity.
COACTIVATOR OF v-Rel
Based on these results, we embarked on a series 
of experiments to determine whether Trip6 could in­
fluence the ability of v-Rel to activate transcription 
in yeast and chicken cells. Except where noted (i.e., 
Fig. 4), we assayed the effect of Trip6 proteins con­
taining aa 116-476 (AN-Trip6) because these se­
quences can efficiently localize to the nucleus and 
contain the three LIM domains that are essential for 
transactivation [see below and (30)].
Trip6 Can Restore the Ability o f  C-Terminal 
Sequences o f  v-Rel to Activate Transcription in 
Yeast
During the course of our characterization of hu­
man Trip6, we noted that a GAL4 DNA binding do- 
main-Trip6 fusion protein could activate transcription 
from a GAL4 site reporter plasmid in yeast (Fig. IB). 
Moreover, similar results were reported by Lee et al. 
(23). Therefore, we wished to determine whether ex­
pression of the Trip6 sequences by themselves (i.e., 
not as a GAD fusion protein) could restore the ability 
of GAL4-3'v-Rel to activate transcription in yeast. As 
shown in Fig. 1C. coexpression of GAL4-3'v-Rel and 
a FLAG-AN-Trip6 fusion protein (containing aa 
116-476 of Trip6) resulted in specific activation of 
transcription from a GAL4 site reporter locus in 
yeast. As controls, expression of the GAL4-3'v-Rel 
protein alone did not activate transcription and the 
FLAG-AN-Trip6 protein did not enable GAL4 se­
quences (aa 1-147) alone to activate transcription. 
These results suggest that Trip6 can, directly or indi­
rectly, bridge an interaction between the C-terminal 
sequences of v-Rel and the general transcription ap­
paratus in yeast.
Trip6 Can Enhance the Ability o f  v-Rel to Activate 
Transcription From a kB Site Reporter Plasmid
We next wished to determine whether Trip6 could 
also enhance the ability of full-length v-Rel to acti­
vate transcription from a promoter containing DNA 
binding sites for v-Rel. Therefore, we determined 
whether FLAG-AN-Trip6 could affect the ability o f ' 
v-Rel to activate transcription from a lacZ  reporter 
plasmid (IgK6) containing six upstream kB sites 
from the mouse kappa light chain gene. Because ver­
tebrate cells have cellular Rel/NF-KB proteins that 
could influence the interpretation of these results, this 
reporter gene experiment was performed in yeast. As 
reported previously (20), full-length v-Rel activated 
transcription from reporter plasmid lgK6 approxi­
mately 10-fold compared to the vector control. Coex­
pression of FLAG-AN-Trip6 resulted in an approxi­
mately twofold further increase in the ability of v-Rel
to activate transcription from IgK6 (Fig. 2). There­
fore, Trip6 is able to enhance transcriptional activa­
tion by full-length v-Rel from a kB site-containing 
promoter.
Trip6 Contains a Transcription Activation Domain 
That Functions in Chicken Fibroblasts
To characterize the activity of Trip6 in vertebrate 
cells, we first determined whether a GAL4-Trip6 fu­
sion protein could activate transcription in chicken 
embryo fibroblasts (CEF). As shown in Fig. 3, 
GAL4-Trip6 activated transcription from a GAL4- 
site CAT reporter plasmid in CEF. As positive con­
trols for these experiments, we also measured tran­
scriptional activation by GAL4-3'v-Rel, which does 
activate transcription in CEF, and GAL4-3'c-Rel, 
which contains a very strong activation domain (28). 
These results indicate that the ability of human Trip6 
sequences to activate transcription is conserved be­
tween yeast and chicken cells.
An N-Terminal Deletion Allows Trip6 to Localize to 
the Nucleus in CEF
For Trip6 to function as a coactivator of transcrip­
tion, it must localize to the nucleus of cells under 
some conditions. We have recently shown that full- 
length mouse Trip6 localizes primarily to adhesion 
plaques in CEF, whereas an N-terminal deletion 
allows mouse Trip6 to enter the nucleus (30). To de­
termine the subcellular localization of human Trip6, 
CEF were transfected with a retroviral expression
40-1
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FIG. 2. Trip6 potentiates transcriptional activation by full-length 
v-Rel from a kB site-containing reporter locus in yeast. Yeast con­
taining kB site reporter plasmid IgK6 was cotransformed with a v- 
Rel expression vector (+) or the corresponding empty vector (-) 
and with a FLAG-ANTrip6 expression vector (+) or the corre­
sponding empty vector (—). Liquid {3-galactosida.se assays were 
performed in triplicate in two separate experiments, which were 
then averaged. Relative fS-galactosidase activities were determined 
by normalizing values to those obtained with double vector 
control cells (value = 1.0).
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FIG. 3. Trip6 sequences can activate transcription in chicken embryo fibroblasts. CEF were cotransfected with a GAL4 site CAT reporter 
plasmid and expression plasmids for the indicated GAL4 fusion proteins. Forty-eight hours later, CAT activity was determined using cell 
lysates that were normalized by an internal lacZ control plasmid. In the case of GAL4-3'c-Rel, which contains a very strong transactivation 
domain, a 10-fold dilution of cell extract was used. Relative CAT activity was calculated by setting the value for GAL4 to 1.0. As in Fig. 
IB. the generalized structures of the Rel proteins are shown above the figure, and the numbers above the figures indicate the aa residues 
included in the proteins.
vector for FLAG-AN-Trip6 (aa 116-476) or with one 
for both FLAG-AN-Trip6 and v-Rel, and indirect im­
munofluorescence was performed with anti-FLAG 
primary antiserum. Much FLAG-AN-Trip6 localizes 
to the nucleus of CEF. whereas full-length human 
Trip6 localizes to adhesion plaques and is excluded 
from the nucleus (Fig. 4, panels 1 and 2). As a con­
trol, wild-type v-Rel is shown to localize to the nu­
cleus of CEF (15) (Fig. 4, panel 3). Furthermore. 
FLAG-AN-Trip6 also localized to the nucleus when 
coexpressed with v-Rel (Fig. 4, panel 4). These re­
sults demonstrate that deletion of N-terminal se­
quences allows human Trip6 to localize to the nu­
cleus.
Coexpression o f Nuclear Trip6 Does Not Affect the 
Transforming Activity o f  v-Rel in Chicken Spleen 
Cells
To determine whether Trip6 could affect the trans­
forming activity of v-Rel, we first created an IRES- 
containing spleen necrosis virus vector for the coex­
pression of v-Rel and FLAG-AN-Trip6. The ability 
of the v-Rel/FLAG-AN-Trip6 vector to transform 
chicken spleen cells was compared to a control vector 
that encoded v-Rel and Neo. As shown in Fig. 5A, 
the transforming activities of these two viral vectors 
were nearly identical. Moreover, cells transformed by 
the v-Rel/FLAG-AN-Trip6 vector expressed both v- 
Rel and FLAG-AN-Trip6 (Fig. 5B). Taken together, 
these results indicate that coexpression of a nuclear
form of human Trip6 does not affect the transforming 
activity of v-Rel.
Trip6 mRNA Is Expressed in Multiple Tissues
To determine the tissue-specific expression pattern 
of Trip6 mRNA. Northern blotting of mRNA from 
multiple human tissues was performed using a Trip6 
probe (Fig. 6). Although the level of expression var­
ies among cell types, Trip6 is expressed as an approx­
imately 1.8 kb mRNA in every tissue tested. Similar 
results have been reported by Lee et al. (23) and Mur- 
thy et al. (24) in a more limited survey of human 
tissues. Of note, even though Trip6 mRNA appears 
to be expressed at quite low levels in lymph node and 
bone marrow, we initially isolated the Trip6 cDNA 
from a human B-cell two-hybrid cDNA library. In 
short, Trip6 appears to be a ubiquitously expressed 
mRNA.
DISCUSSION
In this report, we have identified Trip6 as a likely 
coactivator for transcriptional activation by the v-Rel 
retroviral oncoprotein. Trip6 was initially identified 
in a two-hybrid assay using a portion of the thyroid 
hormone receptor (TR) as bait (23). In those experi­
ments, a region of the rat TR subunit containing the 
ligand binding, dimerization, and transcription activa­
tion domains was used; however, the precise region 
of the TR that interacted with Trip6 was not deter-





FIG. 4. Deletion o f N-terminal sequences enables Trip6 to localize to the nucleus o f CEF. CEF were transfected with expression vectors 
for a FLAG-tagged full-length human Trip6, a FLAG-tagged N-terminally deleted form of human Trip6 (FLAG-AN-Trip6), or both v-Rel 
and FLAG-AN-Trip6. Indirect immunofluorescence was then performed using anti-FLAG or anti-v-Rel antibodies as warranted. (1) FLAG- 
human Trip6 (anti-FLAG), (2) FLAG-AN-Trip6 (anti-FLAG), and (3 and 4) FLAG-AN-Trip6/v-Rel (anti-v-Rel, 3; anti-FLAG, 4). Several 
control (nonexpressing) cells are also visible as nonstaining cells in these panels.
mined. Thus, it is possible that Trip6 interacts with 
the transcription activation domain of the TR, as it 
does with v-Rel. A comparison of the TR aa sequence 
with the C-terminal sequence of v-Rel does not re­
veal any obvious similarities to explain why both pro­
teins interact with Trip6. Trip6 has also been identi­
fied as interacting with three other proteins in two- 
hybrid screens, namely, the tyrosine phosphatase 
PTP1E, the adaptor protein RIL, and the OpaP pro­
tein of Neisseria gonnorrheae (7,24,33).
Trip6 has three LIM domains located towards its
C-terminus. LIM domains are important in several 
settings for mediating protein-protein interactions 
(9). The region of Trip6 that interacts with TR, v-Rel, 
PTP1E, and the OpaP protein in two-hybrid screens 
contains these LIM domains. Thus, it is reasonable to 
suppose that Trip6 interacts with these diverse pro­
teins through its LIM domains.
Trip6 has been proposed to be one of a subfamily 
of LIM domain-containing proteins, which also in­
cludes the highly related protein zyxin, that function 
as intracellular signaling proteins, relaying informa-




















FIG. 5. Coexpression o f  v-Rel and Trip6 in chicken spleen cells. (A) The abilities of the depicted viral vectors to transform chicken spleen 
cells were determined as described in Materials and Methods. Relative transforming activity is relative to the transforming activity of the 
pMFI105 vector (100). Values are the average of 15 independent assays, which were performed in 4 separate experiments. (B) Western blot 
o f  extracts from spleen cells transformed by pMH105 (v-Rel/Neo) or pMH-FLAG-AN-Trip6 (v-Rel/FLAG-AN-Trip6). Filters were first 
probed with anti-FLAG antiserum, then stripped and reprobed with anti-v-Rel antiserum. The lane on the left (AN-Trip6) contains in vitro- 
translated FLAG-AN-Trip6.
tion between adhesion plaques and the nucleus (1). 
Thus, the interaction of Trip6 with plasma membrane 
proteins, such as a tyrosine phosphatase, and with nu­
clear proteins, such as v-Rel and TR, need not be 
surprising. That is, Trip6 may have specific and func­
tional protein-protein interactions at the cell surface 
and in the nucleus. A number of transcription factors, 
including STAT proteins (8), Rel/NF-KB proteins 
(14), sterol regulatory element binding proteins 
(SREBP) (4), and Notch (3), show highly regulated 
cytoplasmic/nuclear shuttling. In each of these cases, 
specific extracellular signals induce nuclear translo­
cation of the transcription factor. There is, however, 
no physiological signal that is known to cause Trip6 
to enter the nucleus of cells. Nevertheless, our results 
[(30) and herein] demonstrate that an N-terminal de­
letion can allow both human and murine Trip6 pro­
teins to localize to the nucleus of CEF, and Nix and 
Beckerle (25) have? shown that an internal deletion
can cause zyxin to accumulate in the nucleus. There­
fore, a cytoplasmic proteolytic processing event (or 
other posttranslational modification) could allow a C- 
terminal fragment of Trip6 to enter the nucleus, 
where it could participate in transcriptional activa­
tion, probably via its LIM domains [(30); Fig. 2 
herein]. This type of proteolytic control is used in the 
SREBP and Notch signaling pathways [reviewed in 
(3,4)].
Only a limited number of transcriptional coactiva­
tors have been identified [reviewed in (17)]. In some 
cases, such as the JAB 1 coactivator of c-Jun, coacti­
vators appear to enhance the DNA binding activity 
of a specific transcription factor (6); of note, Jabl 
also appears to be able to enhance the formation of 
Bc1-3-NF-kB p50 complexes on DNA (iO). In other 
cases, such as what is likely to occur with Trip6 and 
v-Rel, coactivators have their own "activation do­
mains” and bridge interactions between specific tran-




























FIG. 6. Trip6 is expressed in multiple human tissues from a 1.8 
kb mRNA. A Northern blot was performed on filters containing
10 ftg of poly(A)-selected mRNA from the indicated tissues (mul­
tiple tissue blots from Clontech). Longer exposures show expres­
sion in all tissues.
scription factors and the general transcription 
machinery. Interestingly, a LIM domain-containing 
protein. ACT, has recently been identified in a two- 
hybrid screen as an enhancer of transcription activa­
tion by the related CREM and CREB transcription 
factors (12). Like Trip6, ACT has an independent ac­
tivation domain, and ACT associates with CREM via 
its LIM domains (12).
The use o f a coactivator does not, however, ex­
clude the possibility of direct interactions between a 
given transcription factor and the general transcrip­
tion apparatus. For example, C-terminal sequences of 
v-Rel have also been reported to interact weakly with 
TBP and TFIIB (34). In this sense, v-Rel may make 
direct contacts with subunits of the general transcrip­
tion apparatus (e.g.. TBP and TFIIB) and indirect in­
teractions (e.g., through coactivators such as Trip6). 
In cases where multiple interactions occur, the inter­
action between a transcription factor and any isolated 
transcription complex component may be quite weak. 
Indeed, the two-hybrid interaction between v-Rel and 
Trip6 is weaker than most other interactions we have 
tested, and we have been unable to identify condi­
tions under which we can detect a direct interaction 
between Trip6 and v-Rel in vitro (data not shown). 
Therefore, a posttranslational modification or addi­
tional factor may be necessary for the Trip6-v-Rel 
interaction to occur. Along these lines, the two-hy­
brid interaction of Trip6 with the TR is dependent on 
the presence of thyroid hormone (23). Alternatively, 
Trip6 may interact indirectly with v-Rel in cells.
Our results are consistent with Trip6 acting as a 
coactivator for v-Rel in vivo. First, Trip6 contains a 
transcriptional activation domain that can function 
when fused to GAL4 (30) (Figs. IB and 3) or LexA 
(23) in yeast and in chicken fibroblasts. Second, 
Trip6 can enhance transcriptional activation by v-Rel 
(Figs. 1C and 2). Third, an N-terminally deleted form 
of Trip6 can localize to the nucleus of cells (Fig. 4). 
Fourth, as with Rel/NF-KB proteins, Trip6 mRNA is 
expressed in many human cell types, including hema­
topoietic cells (Fig. 6).
Our experiments do not, however, address whether 
Trip6 is required for transcriptional activation and/or 
transformation by v-Rel. In the most obvious sce­
nario, Trip6 could be necessary for v-Rel to activate 
transcription of transformation-specific target genes. 
In this model, overexpression of Trip6 might enhance 
transformation by v-Rel. Alternatively, it is possible 
that Trip6 is a suppressor of transformation, and that 
Trip6 activity must be titrated out by v-Rel for trans­
formation to ensue. In this second model, overexpres­
sion of Trip6 would be expected to suppress transfor­
mation by v-Rel. However, our results show that 
overexpression of an N-terminally deleted, nuclear 
form of human Trip6 does not affect the transforming 
activity of v-Rel (Fig. 5). Nevertheless, this result 
must be interpreted cautiously; for example, we do 
not know whether there is a specific form of Trip6 
that functionally interacts with v-Rel in cells or 
whether there is sufficient functional homology be­
tween chicken and human Trip6 for human Trip6 to 
affect the transforming activity of v-Rel. Future ex­
periments will address the role, if any, of Trip6 in 
transformation by v-Rel. It will also clearly be of in­
terest to determine directly whether Trip6 can func­
216 KOEDOOD ZHAO ET AL.
tion as a coactivator for cellular Rel/NF-KB proteins, 
because Trip6 could represent an additional target for 
therapeutics aimed at disrupting the Rel/NF-KB 
pathway.
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